A Phase IV, prospective, single arm, baseline controlled, multi-centric study for assessment of safety and efficacy of Fixed dose combination (FDC) of Remogliflozin Etabonate, Metformin and Vildagliptin (RMV) in management of Type 2 Diabetes Mellitus (T2DM) patients - TRIAD-RMV

Start Date20 May 2022

Sponsor / Collaborator

Glenmark Pharmaceuticals Ltd.

CTRI/2021/08/035354

/ RecruitingPhase 3

Remogliflozin in patients with type 2 diabetes hospitalized for acute decompensated heart failure - Remo Safe-AHF Study

Start Date16 Aug 2021

Sponsor / Collaborator-

CTRI/2021/03/032005

/ CompletedNot ApplicableIIT

A PROSPECTIVE MULTICENTER RANDOMIZED OPEN LABEL, ACTIVE CONTROLLED STUDY TO ASSESS EFFECT OF REMOGLIFLOZIN COMPARED TO DAPAGLIFLOZIN ON 24 HOUR GLUCOSE PROFILE ASSESSED BY CONTINUOUS GLUCOSE MONITORING IN INDIAN PATIENTS OF TYPE 2 DIABETES MELLITUS. - REMIT-GV

Start Date15 Mar 2021

Sponsor / Collaborator-

100 Clinical Results associated with Remogliflozin etabonate

100 Translational Medicine associated with Remogliflozin etabonate

100 Patents (Medical) associated with Remogliflozin etabonate

Literatures (Medical) associated with Remogliflozin etabonate

15 Nov 2025·JOURNAL OF CHROMATOGRAPHIC SCIENCE

Reverse-Phase Liquid Chromatography Method Development and Validation for Simultaneous Estimation of Drugs: Remogliflozin, Metformin and Vildagliptin

Article

Author: Ghadagepatil, Nilam A ; Kukade, Samruddhi S ; Bansode, Amol S ; Gaikwad, Shubhangee S ; Bagul, Shweta S

Abstract:

A precise, fast and efficient technique utilizing reverse-phase liquid chromatography was established for the simultaneous estimation of Remogliflozin, Metformin and Vildagliptin, in a commercial pharmaceutical preparation. The method utilized a HiQ Sil C18 analytical column having a size of 250 × 4.6 mm and particle size utilized was 5 μm. The mobile phase composition comprised a mixture of potassium dihydrogen orthophosphate buffer (pH 4.7), methanol and acetonitrile in a ratio of 20:55:25 v/v/v. The flow rate was adjusted to 1.2 mL/min. Three UV wavelengths were finalized for Remogliflozin (276 nm), Metformin (227 nm) and Vildagliptin (213 nm), but the detection wavelength utilized for HPLC was 210 nm (isosbestic point). After validation, it was observed that the method exhibited linearity, as evidenced by correlation coefficients of 0.9994, 0.9997 and 0.9980 for Remogliflozin, Metformin and Vildagliptin, respectively. The recovery values for the three compounds were found 103.42%, 100.39% and 99.97%. Additionally, the relative standard deviation for six replicates consistently remained below 2%. This HPLC method was effectively employed for the quantitative analysis of the target drugs in tablet formulations.

01 Oct 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Chemoenzymatic synthesis of remogliflozin etabonate, an antidiabetic agent sodium-glucose cotransporter 2 inhibitor, using UDP-glucosyltransferase

Article

Author: Yamaguchi, Takuya ; Chakraborty, Joy ; Asano, Yasuhisa ; Kato, Yasuo ; Izawa, Yu

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic drugs developed using phlorizin, a natural glucoside, as the lead compound. Chemical glycosylation requires multi-step reactions involving protection and deprotection steps, posing challenges in terms of regioselectivity and environmental burden due to the use of hazardous reagents and harsh conditions. In contrast, enzymatic glycosylation using UDP-glucosyltransferases (UGTs) enables regio- and stereoselective glycosylation under mild conditions without protection and deprotection steps. In this study, we developed a chemoenzymatic hybrid synthesis method for remogliflozin etabonate, an SGLT2 inhibitor approved in India in 2019, using UGT-catalyzed glucosylation as a key step. Screening plant and bacterial UGTs led to the identification of UGTs from Bacillus that efficiently catalyze the glucosylation of chemically synthesized remogliflozin aglycon. Using this enzyme in combination with a UDP-glucose regeneration system that employs soybean sucrose synthase and cyclodextrin encapsulation to improve substrate solubility, we synthesized remogliflozin at a concentration of approximately 13 g/L with 95 % conversion. These findings highlight the potential of UGT-catalyzed glycosylation as a mild and efficient approach for the synthesis of glycosylated pharmaceutical compounds.

09 Apr 2025·Journal of the American Chemical Society

Kinetic Steering of Amyloid Formation and Polymorphism by Canagliflozin, a Type-2 Diabetes Drug

Article

Author: Alexander I. P. Taylor ; Martin Wilkinson ; Alice Brinkworth ; Richard Foster ; Yong Xu ; Sheena E. Radford ; Neil A. Ranson ; Anastasia Zhuravleva ; Pijush Chakraborty ; Leon F. Willis

Amyloid formation is involved in widespread health conditions such as Alzheimer's disease, Parkinson's disease, and type-2 diabetes. Amyloid fibrils have a similar cross-β architecture, but fibrils formed by a single protein sequence can have diverse structures, varying with time, self-assembly conditions, and sequence modifications. Fibril structure has been proposed to be diagnostic of disease, but why different structures result under different conditions, especially in vitro, remains elusive. We previously identified a small molecule, YX-I-1, which inhibits in vitro amyloid formation by islet amyloid polypeptide (IAPP), a peptide hormone whose amyloid formation is involved in type-2 diabetes. Here, using YX-I-1 as a lead, we identified regulator-approved drugs with similar structures by chemical similarity analysis and substructure searches and monitored the effect of 24 of these potential ligands on IAPP amyloid assembly in vitro. We show that one such compound, canagliflozin (Invokana), a type-2 diabetes drug already in clinical use, can strongly delay the kinetics of IAPP amyloid formation, an activity independent of its intended mode of action [sodium-glucose linked transporter 2 (SGLT2) inhibitor] that may have important therapeutic implications. Combining analysis of amyloid self-assembly kinetics, biophysical characterization of monomer and fibril binding, and cryo-EM of the assembly products, we show that YX-I-1 and canagliflozin target IAPP early in aggregation, remodeling the energy landscape of primary nucleation and profoundly altering the resulting fibril structures. Early binding events thus imprint long-lasting effects on the amyloid structures that form.

News (Medical) associated with Remogliflozin etabonate

25 Dec 2023

·synapse.patsnap.com

Deciphering SGLT2 Inhibitors and Keeping Up with Their Recent Developments

SGLT2, or sodium-glucose co-transporter 2, is a protein found in the kidneys that plays a crucial role in glucose reabsorption. It is responsible for the reabsorption of glucose from the urine back into the bloodstream. By inhibiting SGLT2, glucose excretion is increased, leading to lower blood glucose levels. This mechanism is particularly important in individuals with type 2 diabetes, as it helps to reduce hyperglycemia. SGLT2 inhibitors are a class of medications that target this protein, providing an effective treatment option for managing diabetes and improving glycemic control. SGLT2 inhibitors mainly work by inhibiting SGLT2 in renal tubules, reducing the renal glucose threshold, reducing the reabsorption of glucose by renal tubules, increasing the excretion of glucose in urine, and thereby lowering plasma glucose levels. With the conduct of clinical research, the hypoglycemic efficacy and safety of SGLT2 inhibitors have been fully confirmed in global clinical studies. Cardiovascular outcome studies of SGLT2 inhibitors have confirmed that they can significantly reduce the risk of cardiovascular events in patients with type 2 diabetes. Among them, the DECLARE-TIMI58 study showed that dapagliflozin reduced the risk of heart failure hospitalization or cardiovascular (CV) death by 17% (p=0.005), and did not increase the risk of major adverse cardiovascular events (MACE) (p=0.17); other studies have shown the benefits of SGLT2 inhibitors in delaying the progression of end-stage renal disease: dapagliflozin can delay the time for CKD patients to enter end-stage renal disease by 6.6 years. In addition, in terms of diabetes-related complications, exploratory studies of SGLT2 inhibitors have also achieved results. At this year’s American Diabetes Association (ADA) annual meeting, two studies from Japan showed that SGLT2 inhibitors can improve diabetic neuropathy and impaired oxidative muscle function in patients with type 2 diabetes. The progress of evidence promotes the update of the guidelines. The 2023 latest version of ADA diabetes clearly points out that for patients with type 2 diabetes with high cardiovascular and renal risk, drugs such as SGLT2 inhibitors need to be part of the strategy to lower blood sugar and comprehensively reduce cardiovascular and renal risk, and can be independent of HbA1c targets. The status of SGLT2 inhibitors in the treatment of type 2 diabetes has been further improved. The analysis of the target SGLT2 reveals a competitive landscape with multiple companies actively involved in the development of drugs. C.H. Boehringer Sohn AG & Co. KG, Merck & Co., Inc., AstraZeneca PLC, Daewoong Co., Ltd., and Johnson & Johnson are the companies growing fastest under the target SGLT2. The most common indication for approved drugs is Diabetes Mellitus, Type 2. Small molecule drugs dominate the drug types progressing rapidly under the target SGLT2. The United States, European Union, and China are the countries/locations with the highest development progress. The target SGLT2 shows promising future development with ongoing research and development efforts by various companies and countries/locations. How do they work?SGLT2 inhibitors are a type of medication used in the treatment of type 2 diabetes mellitus. SGLT2 stands for sodium-glucose co-transporter 2, which is a protein responsible for reabsorbing glucose in the kidneys. By inhibiting this protein, SGLT2 inhibitors help to lower blood glucose levels by increasing the amount of glucose excreted in the urine. From a biomedical perspective, SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, allowing excess glucose to be eliminated from the body. This mechanism of action helps to reduce blood glucose levels and improve glycemic control in patients with type 2 diabetes. It is important to note that SGLT2 inhibitors are not suitable for everyone and should be used under the guidance of a healthcare professional. They have been shown to have additional benefits beyond glycemic control, such as promoting weight loss and reducing the risk of cardiovascular events. However, they may also have side effects, including an increased risk of urinary tract infections and genital mycotic infections. Therefore, it is crucial for patients to discuss the potential risks and benefits of SGLT2 inhibitors with their healthcare provider before starting this medication. List of SGLT2 InhibitorsThe currently marketed SGLT2 inhibitors include: Enavogliflozin/METFORMIN HYDROCHLORIDEGemigliptin/DapagliflozinBexagliflozinEnavogliflozinHenagliflozein ProlineEmpagliflozin/Linagliptin/Metformin HydrochlorideMetformin/Remogliflozin etabonateRemogliflozin etabonateSotagliflozinErtugliflozinFor more information, please click on the image below. What are SGLT2 inhibitors used for?SGLT2 inhibitors have been studied for their potential in treating various conditions. They are particularly promising in the following areas Type 2 Diabetes Mellitus；Chronic Kidney Disease；Heart Failure. For more information, please click on the image below to log in and search. How to obtain the latest development progress of SGLT2 inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of SGLT2 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

14 Nov 2023

·synapse.patsnap.com

What are AMPK inhibitors and how do you quickly get the latest development progress?

AMP-activated Protein Kinase (AMPK) is a heterotrimeric protein consisting of alpha (α) subunit (63kD), beta (β) (30kD), and gamma (γ) (37-63kD) subunits. The alpha subunit has a catalytic role, while the beta and gamma subunits serve important roles in maintaining the stability of the trimer and the specificity of the substrates. When AMP binds to the gamma subunit, it induces a conformational change that activates the complex, making it more susceptible to phosphorylation activation by upstream kinases of AMPK. AMPK maintains cellular energy balance by affecting multiple stages of cellular metabolism. When intracellular ATP levels decrease, AMPK inhibits glycogen, fat, and cholesterol synthesis to reduce ATP usage, and promotes fatty acid oxidation and glucose transport to increase ATP production. Hence, AMPK is considered a switch regulating cellular energy metabolism. As a low ATP sensor, AMPK maintains ATP homeostasis and adjusts downstream signaling pathways to maintain optimal mitochondrial status. Mitochondrial damage or lack of AMPK activation, including respiratory chain complex inhibitors such as the diabetes drug metformin, rotenone a Parkinson's-disease causing herbicide, proton clusters, ATP synthase inhibitors and mitochondrial DNA depletion or mutations, AMPK becomes the protector of mitochondria. In yeast 206, Caenorhabditis elegans 207-209, and Drosophila 210, AMPK is linked with mitochondria, representing an evolutionarily conserved function of AMPK. In eukaryotes, AMPK is activated when mitochondrial function or ATP production is impaired. Interestingly, there is no excess of AMPK substrates to maintain mitochondrial health, as mitochondrial integrity is the central medium of cellular energetics. The preference for specific AMPK complexes to locate at or near mitochondria and respond to mitochondrial-specific stressors is yet to be investigated. In lysosomes, how the mitochondrial pool of AMPK interacts or relates to LKB156 is an interesting area for future research. Further study is required to understand how the interactions among mitochondria, AMPK, ULK1 and other kinases activated by energy stressors like PINK1 and TBK1, and differential protein phosphorylation, influence mitochondrial autophagy and cell division and/or fusion and apoptosis177,211-213. Interestingly, recent research has found that the pluripotency of immune cells and stem cells involve mitochondrial dynamics and health214-218. Finally, expanding the substrate pool of mitochondrial AMPK will aid in researching novel mechanisms through which AMPK regulates mitochondrial function. Given that metformin is an effective AMPK activator, these issues not only bear importance for understanding basic biology but also provide implications for over 150 million individuals worldwide who take metformin. Furthermore, research on the direct activators of AMPK for the treatment of cancer and metabolic diseases (Box 1) has underscored the importance of AMPK in biology, particularly mitochondrial biology, in relation to metabolism. The regulation of mitochondrial health by metformin and other AMPK activators is one mechanism through which type 2 diabetes can be ameliorated, and is also one of the reasons why exercise and caloric restriction can improve health and extend the lifespan. How do they work?From a biomedical perspective, AMPK inhibitors refer to a class of drugs or compounds that inhibit the activity of adenosine monophosphate-activated protein kinase (AMPK). AMPK is an enzyme that plays a crucial role in regulating cellular energy homeostasis. It is activated when cellular energy levels are low, and it helps restore energy balance by promoting processes such as glucose uptake and fatty acid oxidation, while inhibiting energy-consuming pathways like protein synthesis. AMPK inhibitors, on the other hand, work by blocking the activation or function of AMPK. By doing so, they can modulate various cellular processes and signaling pathways. These inhibitors have been studied for their potential therapeutic applications in various diseases, including cancer, metabolic disorders, and neurodegenerative diseases. In cancer research, AMPK inhibitors have been investigated as potential anti-cancer agents. By inhibiting AMPK, these drugs aim to disrupt cancer cell metabolism, which is often dysregulated and dependent on altered energy pathways. Additionally, AMPK inhibitors may also enhance the efficacy of other anti-cancer treatments, such as chemotherapy or radiation therapy. In the context of metabolic disorders like type 2 diabetes and obesity, AMPK inhibitors have been explored as a potential strategy to modulate glucose and lipid metabolism. By inhibiting AMPK, these compounds may alter the balance between energy storage and utilization, potentially leading to improved glucose control and weight management. It's important to note that the development and use of AMPK inhibitors require careful consideration of their potential side effects and impact on normal cellular functions. While these inhibitors hold promise as therapeutic agents, further research is needed to fully understand their mechanisms of action and evaluate their safety and efficacy in clinical settings. List of AMPK InhibitorsThe currently marketed AMPK inhibitors include: Sitagliptin/Metformin HydrochlorideEnavogliflozin/METFORMIN HYDROCHLORIDEMetformin Hydrochloride/Sitagliptin HydrochlorideEmpagliflozin/Linagliptin/Metformin HydrochlorideMetformin/Remogliflozin etabonateAnagliptin/Metformin HydrochlorideAtorvastatin Calcium Hydrate/Metformin HydrochlorideErtugliflozin/Metformin HydrochlorideEvogliptin Tartrate/Metformin HydrochlorideEmpagliflozin/metformin HydrochlorideFor more information, please click on the image below. What are AMPK inhibitors used for?AMPK inhibitors has long been in the spotlight as a potential target for the treatment of diseases associated with metabolic disorders, including diabetes, obesity and fatty liver, as well as cancer. For more information, please click on the image below to log in and search. How to obtain the latest development progress of AMPK inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of AMPK inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

10 Aug 2022

·www.biospace.com

Fast Approval Of Novel Drugs For The Treatment Has Pushed Diabetic Neuropathy Market To Growth By 5.5% CAGR During The Forecast Period.

By End User, The Peripheral Neuropathy Disorder Is Expected To Witness 5.9% CAGR, Owing To Surge In Usage Of Diabetic Neuropathy Formulations In This Segment Fact.MR – A Market Research and Competitive Intelligence Provider: The global diabetic neuropathy market is expected to witness a CAGR of 5.9% during the forecast period (2020-2025) Diabetes is the most common chronic conditions, affecting millions of patients globally. Imbalanced diets and changing lifestyle are the major factors responsible for increased incidence of diabetes. The approval of novel drugs for the treatment of various diabetic problems such as diabetic neuropathic pain has pushed the growth of the diabetic neuropathy market. For instance, In 2015, the Food Drug and Administration (FDA) had approved Nucynta ER for the treatment of neuropathic pain caused by diabetes. In addition to this, the peripheral neuropathy disorder segment is expected to boost the growth of the market. Moreover, the peripheral neuropathy disorder is used in various application areas. Also, increased usage of diabetic neuropathy has been witnessed in the last few years. In addition to this, the scope of peripheral neuropathy drugs is expected to expand, as the treatment is currently confined on managing pain. For More Insights on this Market, Get A Sample Report! Besides this, an increase in the patients suffering from proximal neuropathy is expected to drive the growth of diabetic neuropathy market. Along with this, growing government investments in research for new drugs and therapies are anticipated to boost the market growth prospects. For instance, the National Institute of Neurological Disorders (NIND) and Stroke funded research on neuropathy. Moreover, high percentage of patients getting diagnosed with diabetic neuropathy is contributing to the share of the market. In addition to this, inadequate healthcare infrastructure and lack of good dietary habits are motivating companies to invest in research and develop new pipeline drugs. Key Takeaways: North America is expected to witness prominent usage of diabetic neuropathy drugs market during the forecast period. Asia Pacific is expected to offer profitable opportunities and is anticipated to witness 1.5X of the growth during the forecast period. This is due to large patient pool and supportive government policies in the region. Growth Drivers: Lack of treatments reversing underlying nerve damage has pushed healthcare providers to increase research and development to find a potential solution. Fast approval of drugs for the treatment of diabetic neuropathic pain has led to a major growth in the market. For instance, Lyrica, has been approved for neuropathic pain treatment in 130 countries. Inadequate healthcare infrastructure and lack of good dietary habits in Asia Pacific is pushing medical companies to make significant investments in drug development. Restraints: Covid-19 pandemic has limited the production of novel drugs or supplies of insulin to hospitals, pharmacies. Also, this has led to delays in the processing orders. Moreover, Covid-19 had a restraining impact on the production of diabetic drugs across all regions. To Gain In-Depth Insights on Diabetic Neuropathy Market, Request Methodology at Competitive Landscape: The market is highly consolidated in nature. Key players in the market are Pfizer Inc., Arbor Pharmaceuticals., Janssen Global Services, LLC, Eli Lilly, Deposed, Inc., NeuroMatrix, Inc. For instance, Janssen Global Services, LLC, offers diabetic neuropathy drugs such as NUCYNTA, NUCYNTA ER, Duragesic and INVOKANA. Moreover, these drugs contain canagliflozin and tapentadol which are important for regulating blood sugar levels. Similarly, Pfizer, Inc. manufactures Celebrex, Lyrica EH, and Tafamidis Meglumine. Glenmark Pharmaceuticals Ltd., offers remoglifozin etabonate, belonging to the gliflozin class to treat type-2 diabetes. Additionally, the company has successfully out-licensed seven novel molecules to leading pharmaceutical giants such as Merck KGaA and remains the only company to execute multiple deals on novel molecules. Key Companies Profiled by Fact.MR Pfizer Inc. Arbor Pharmaceuticals Janssen Global Services, LLC Eli Lilly Deposed, Inc. NeuroMatrix, Inc. More Valuable Insights on Diabetic Neuropathy Market Research Segmentation of Diabetic Neuropathy Market Research Disorder Peripheral Neuropathy Autonomic Neuropathy Proximal Neuropathy Focal Neuropathy Treatment Drugs Analgesic Topical: Capsaicin Others Opioid: Morphine Others NSAIDs: Ibuprofen Naproxen Others Antidepressants: TCAs: Amitriptyline Imipramine Others SNRIs: Duloxetine Others SSRIs: Citalopram Paroxetine Others Anticonvulsant Drugs: Gabapentin Pregabalin Topiramate Others Other Drugs Radiotherapy: Transcutaneous Electrical Nerve Stimulation (TENS) Others Physiotherapy Distribution Channel Hospitals Clinics Retail Pharmacy Online Pharmacy Region North America Europe Asia Pacific Latin America Middle East & Africa (MEA) Interested to Procure The Data? Inquire here Explore Fact.MR's Coverage on the Healthcare Domain- Diabetic Food Market - Diabetic Food Market Share & Trends Analysis, By Nature (Organic, Conventional), By Type (Bakery Products, Dairy Products, Others), By Distribution Channel (Direct, Indirect) & By Region Forecast - Global Market Insights 2018 to 2028 Urodynamic Devices Market - The primary objective of an urodynamic test is understanding disorders/problems occurring in lower urinary tract by duplication of symptoms. Urodynamic study also help in determination of the causes of bladder dysfunction, formulating an appropriate course for the treatment. Recombinant Protein Market – Proteins resulting from expression of recombinant DNA (rDNA), within living cells, are known as recombinant proteins. rDNAs are DNA molecules that are formed by laboratory procedures of genetic recombination, to bring genetic material together from multiple sources. Gas Chromatography Market - Gas chromatography (GC) is used for analysis and separation of compounds, which are capable of vaporizing without undergoing decomposition. GC is used for testing purity of substances, separating the components in a mixture. Gas chromatography is also being used for preparing pure compounds from mixtures, and identifying the compounds. Antibodies Market - The global demand for antibodies is expected to remain moderate in the forthcoming years. Increasing prevalence of chronic ailments such as autoimmune diseases, cancer, diabetes and others is encouraging manufacturers to step up investments in R&D activities pertaining to antibodies. Amniocentesis Needle Market - Demand for the amniocentesis needles is expected to gain momentum attributed to growing need for removing excessive amniotic fluid from around the baby. Excessive amniotic fluid during pregnancy leads to increasing risks of complication. Prefilled Syringes Market - The global market for prefilled syringes is expected to grow at a value CAGR of nearly 10% from 2021 to 2031. Short-term forecast appears equally lucrative, registering a growth rate of 9.6% until 2026. Actigraphy Sensors & PSG Devices Market - The actigraphy sensor and PSG devices market is witnessing positive growth with the frontrunners accounting for nearly two-third of the total revenue in the market. Frontrunners in the actigraphy sensor and PSG devices market, including Koninklijke Philips N.V., Fitbit, Inc., Garmin Ltd., and ResMed Inc., have maintained a strong foothold in the market. Lithotripsy Devices Market - The lithotripsy devices market is anticipated to surpass US$ 2 Billion by 2031- trailing at a CAGR of over 5%. The market is largely driven by the increased prevalence of urolithiasis, an increase in the number of extracorporeal shock waves lithotripsy operations, technical developments, and rising awareness. About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

Antibody

100 Deals associated with Remogliflozin etabonate

External Link

KEGG	Wiki	ATC	Drug Bank
D10055	Remogliflozin etabonate	A10B	DB12935

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	India	-	26 Apr 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Dysfunction Associated Steatohepatitis	Phase 2	United States	Avolynt, Inc.	14 Jun 2016
Diabetes Mellitus, Type 1	Phase 2	United States	GSK Plc	31 Mar 2008
Obesity	Phase 1	United Kingdom	GSK Plc	29 Sep 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTRI/2020/02/023120 (Pubmed)	Not Applicable	Diabetes Mellitus, Type 2	60	瑞格列净+二甲双胍	rzckcxonmy(ongwihfabe) = aueqnjiyfp azfybmoddq (loqppyptrk ) View more	Positive	01 May 2024
				维格列汀+二甲双胍	rzckcxonmy(ongwihfabe) = cwcqgcrnsq azfybmoddq (loqppyptrk ) View more
ADA2021	Not Applicable	Diabetes Mellitus, Type 2	182	Remogliflozin Etabonate 100mg + Vildagliptin 50mg	lhtgkgyfds(wfatpbneox) = lqvjdmwbwz zbooepqhio (ctzlfvkilf )	Positive	01 Jun 2021
				Empagliflozin 25mg + Linagliptin 5mg	lhtgkgyfds(wfatpbneox) = hmgpqmlfnc zbooepqhio (ctzlfvkilf )
ADA2020	Not Applicable	Add-on	120	Remogliflozin 100 mg	ziglmitlbe(jhtpyhwtaf) = xdkhmcdzwb fmpoqzpmkq (xkvgwqaryo ) View more	-	01 Jun 2020
				Canagliflozin 300 mg	ziglmitlbe(jhtpyhwtaf) = nbtbunhyuq fmpoqzpmkq (xkvgwqaryo ) View more
NCT00500331 (CTgov)	Phase 2	Diabetes Mellitus, Type 2	334	placebo (Placebo)	uuhajysfsc(lyxgylcvnr) = wkatkgxdgl tgcbpmndep (farhnfdcuq, 0.107) View more	-	06 Dec 2017
				GSK189075 (GSK189075 50 mg)	uuhajysfsc(lyxgylcvnr) = dwidtzsijv tgcbpmndep (farhnfdcuq, 0.105) View more
NCT00495469 (CTgov)	Phase 2	Diabetes Mellitus, Type 2	250	Placebo	zqntvkgsih(jssxgwclbq) = hxerrlywyv lkqgfpdffs (yyqhwiwzck, 0.141) View more	-	30 Oct 2017
NCT00575159 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	10	placebo+GSK189075 (Placebo)	tyyntukxmi = farxvjoepw dhvmckvpwr (yierogvuge, bxivbualrb - juigxnkchp) View more	-	09 Oct 2017
				Placebo (Placebo+ Prandial Insulin)	tyyntukxmi = bsnhyarpfp dhvmckvpwr (yierogvuge, fejwslmnrm - dstusrkubn) View more
NCT02537470 (Accesswire) Manual	Phase 2	Diabetes Mellitus, Type 2	191	Remogliflozin	qxdufgusrc(ckojcbpemd) = All three doses examined caused statistically significant decreases in placebo-adjusted HbA1c ranging qbajdzarzd (mdwcotpevt ) View more	Positive	19 Dec 2016
				Placebo
NCT01571661 (Pubmed \| BMC Pharmacol Toxicol)	Phase 1	Diabetes Mellitus, Type 2	16	Remogliflozin etabonate	eubhabhubr(cuzwdekhvh) = mtebpzptpk gimijznihd (ampzcxkzoj ) View more	-	13 May 2013
				Placebo	dlxdntqlld(hjkzfpjctb) = kijvhtmfej rmwahmjeho (mtjbeakmuq )
NCT00575159 (Pubmed \| Diabetes Care)	Phase 2	Diabetes Mellitus, Type 1	10	Remogliflozin etabonate 150 mg	rzvixvyovs(thufakobqr) = xvejysmskp ojpikikkrg (utxcgosnvk )	-	01 Nov 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Remogliflozin etabonate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation